Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report) were down 7.2% during trading on Wednesday . The stock traded as low as $5.69 and last traded at $5.6260. 63,258 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 324,480 shares. The stock had previously closed at $6.06.
Wall Street Analyst Weigh In
A number of analysts have issued reports on the company. Wall Street Zen lowered Regencell Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.
Check Out Our Latest Stock Report on Regencell Bioscience
Regencell Bioscience Price Performance
Regencell Bioscience (NASDAQ:RGC – Get Free Report) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Regencell Bioscience
Large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC acquired a new stake in Regencell Bioscience during the 2nd quarter worth approximately $1,701,000. BNP Paribas Financial Markets purchased a new position in Regencell Bioscience in the 2nd quarter valued at approximately $768,000. XTX Topco Ltd acquired a new position in shares of Regencell Bioscience in the third quarter worth $598,000. Hudson Bay Capital Management LP acquired a new position in shares of Regencell Bioscience in the fourth quarter worth $275,000. Finally, Vident Advisory LLC increased its position in shares of Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after acquiring an additional 11,866 shares during the period. 0.13% of the stock is owned by hedge funds and other institutional investors.
Regencell Bioscience Company Profile
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Read More
- Five stocks we like better than Regencell Bioscience
- Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet
- Velo3D Forges a New Reality After Its Sharp Stock Sell-Off
- Why Apple Could Be the Last One Standing in the Tech Wreck
- GE Sparks a High-Voltage Aviation Breakout
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
